SIGA TECHNOLOGIES INC
SIGA$302M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK39 employees
SIGA Technologies, Inc. is an American pharmaceutical company founded in 1995, based in New York City, which develops and sells pharmaceutical solutions for the antiviral treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 4, 2026
6wMarket Overview
Stock performance and key metrics
SIGA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
tecovirimat
Smallpox
TPOXX
Smallpox
Smallpox and Mpox Vaccine
Smallpox
ST-246 400 mg
Orthopoxviral Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
tecovirimat | Phase 3 | Smallpox | - | - |
TPOXX | Phase 3 | Smallpox | - | - |
Smallpox and Mpox Vaccine | Phase 2 | Smallpox | - | - |
ST-246 400 mg | Phase 2 | Orthopoxviral Disease | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply